BioSpace News Archive

Brooklyn ImmunoTherapeutics , Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, today announced it has paid $1 million towards the acquisition of a license for Factor Bioscience’s and Novellus’ mRNA Gene Editing and Cell Therapies technology and has extended through May 21, 2021 its option exercise period

Dow Inc. is pleased to report the preliminary results of its 2021 Annual Meeting of Stockholders.

Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the recent launch of CREO ONE™, the market’s first robotic screw designed for spine surgery with ExcelsiusGPS

Phase 2/3 clinical trial for Tempol for the prevention of hospitalizations in patients with COVID-19 expected to initiate in the second quarter of 2021 Management to host webcast/conference call today at 2 p.m. PDT / 5 p.m. EDT

Encompass Health Corp. (NYSE: EHC) today announced a time change of its previously announced 2021 first quarter earnings conference call. In order to facilitate analysts’ ability to participate in both the Company’s and another healthcare company’s call, the call will be moved from 9 a.m. ET to 10 a.m. ET on April 28, 2021.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Alan List, M.D. has been appointed as the Company’s Chief Medical Officer and a member of the senior leadership team at Precision BioSciences.

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its first quarter 2021 financial results after the close of the market on Thursday, May 6, 2021 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that it has recently expanded its investor and media outreach platform in order to enhance communication with investors and increase investor awareness of and interest in the Company, its product candidates, and its clinical programs.

ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Cara Cassino, MD, Chief Medical Officer and Executive Vice President of Research,

Envista Holdings Corporation (NYSE: NVST) (“Envista”) will report financial results for its first quarter 2021 on Wednesday, May 5, 2021.